➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Merck
McKinsey
McKesson
Express Scripts

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Albireo Company Profile


Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for ALBIREO, and when can generic versions of ALBIREO drugs launch?

ALBIREO has one approved drug.

There are seven US patents protecting ALBIREO drugs.

There are one hundred and twelve patent family members on ALBIREO drugs in forty-five countries.

Summary for Albireo
International Patents:112
US Patents:7
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Albireo

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Albireo BYLVAY odevixibat CAPSULE;ORAL 215498-004 Jul 20, 2021 RX Yes Yes 10,487,111 ⤷  Free Forever Trial ⤷  Free Forever Trial
Albireo BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-003 Jul 20, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial
Albireo BYLVAY odevixibat CAPSULE;ORAL 215498-004 Jul 20, 2021 RX Yes Yes 9,694,018 ⤷  Free Forever Trial ⤷  Free Forever Trial
Albireo BYLVAY odevixibat CAPSULE;ORAL 215498-002 Jul 20, 2021 RX Yes No 7,132,416 ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Albireo BYLVAY odevixibat CAPSULE;ORAL 215498-002 Jul 20, 2021 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Johnson and Johnson
McKinsey
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.